We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+8.36%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$184M
Cap. Flow
+$269M
Cap. Flow %
24.82%
Top 10 Hldgs %
42.57%
Holding
126
New
25
Increased
29
Reduced
26
Closed
35

Top Buys

Rank Stock Value
1
TMCI icon
Treace Medical Concepts
TMCI
+$34.9M
2
TGTX icon
TG Therapeutics
TGTX
+$34.1M
3
GSK icon
GSK
GSK
+$33.5M
4
PODD icon
Insulet
PODD
+$28.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.8M

Top Sells

Rank Stock Value
1
CRL icon
Charles River Laboratories
CRL
+$23.3M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$13.7M
3
ACLX
Arcellx
ACLX
+$12.3M
4
CVS icon
CVS Health
CVS
+$11.5M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.95M

Sector Composition

Rank Sector Weight
1 Healthcare 90.02%
2 Consumer Staples 1.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
26
Krystal Biotech
KRYS
$9.64B
$13.7M 1.26%
117,892
+7,700
+7% +$939K
SIBN icon
27
SI-BONE Inc
SIBN
$800M
$13.6M 1.26%
642,289
+16,145
+3% +$374K
CVS icon
28
CVS Health
CVS
$126B
$13.4M 1.24%
192,554
-162,500
-46% -$11.5M
ATRC icon
29
AtriCure
ATRC
$2B
$13.4M 1.24%
+306,000
New +$14.9M
EPIX
30
DELISTED
ESSA Pharma
EPIX
$13.2M 1.22%
4,287,094
+85,000
+2% +$245K
MREO
31
Mereo BioPharma
MREO
$48.4M
$12.5M 1.15%
+9,677,419
New +$12.8M
BHC icon
32
Bausch Health
BHC
$2.35B
$11.6M 1.07%
1,408,801
+253,301
+22% +$2.18M
VSTM icon
33
Verastem
VSTM
$516M
$11M 1.01%
1,347,369
+827,000
+159% +$7.94M
BNTX icon
34
BioNTech
BNTX
$23.3B
$10.6M 0.98%
+98,000
New +$10.8M
INBX
35
DELISTED
Inhibrx, Inc. Common Stock
INBX
$10.1M 0.93%
549,183
+76,000
+16% +$1.59M
RYZB
36
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$10M 0.92%
+451,163
New +$9.47M
SLNO
37
DELISTED
Soleno Therapeutics
SLNO
$9.59M 0.88%
+325,000
New +$1.97M
MRUS
38
DELISTED
Merus
MRUS
$9.07M 0.84%
+384,490
New +$9.32M
BCYC
39
Bicycle Therapeutics
BCYC
$277M
$7.87M 0.73%
391,800
-20,000
-5% -$457K
BCAB icon
40
BioAtla
BCAB
$5.53M
$7.41M 0.68%
87,124
+700
+0.8% +$89.2K
PHVS icon
41
Pharvaris
PHVS
$2.34B
$7.18M 0.66%
343,975
-47,925
-12% -$883K
CMPS
42
Compass Pathways
CMPS
$1.83B
$7.14M 0.66%
+964,550
New +$8.54M
NUVL
43
DELISTED
Nuvalent
NUVL
$7.1M 0.65%
154,416
-58,584
-28% -$2.6M
INSP icon
44
Inspire Medical Systems
INSP
$1.73B
$7.06M 0.65%
35,600
+28,900
+431% +$7.29M
EXAS
45
DELISTED
Exact Sciences
EXAS
$6.97M 0.64%
102,196
+32,696
+47% +$2.77M
NRIX icon
46
Nurix Therapeutics
NRIX
$2.61B
$6.4M 0.59%
+814,000
New +$7.43M
BLFS icon
47
BioLife Solutions
BLFS
$1.65B
$6.06M 0.56%
+439,000
New +$6.92M
JSPR icon
48
Jasper Therapeutics
JSPR
$22M
$5.81M 0.54%
830,098
+52,500
+7% +$641K
IOVA icon
49
Iovance Biotherapeutics
IOVA
$1.94B
$5.64M 0.52%
1,239,777
– –
NVCR icon
50
NovoCure
NVCR
$1.87B
$5.56M 0.51%
344,100
+99,000
+40% +$2.85M
1
2
3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Soleus Capital Management held 126 positions worth $1.08B, up 20% from $900M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Soleus Capital Management deployed $269M of net new capital in Q3 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Treace Medical Concepts: 1,907,823 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Charles River Laboratories, an estimated $23.3M trimmed.

  • Soleus Capital Management's largest Q3 2023 buy was Treace Medical Concepts: 1,907,823 shares worth $25M.
  • Soleus Capital Management added most to TG Therapeutics in Q3 2023, an estimated $34.1M increase.
  • Soleus Capital Management's biggest Q3 2023 reduction was Charles River Laboratories, cutting an estimated $23.3M.
  • Soleus Capital Management fully exited Seagen Inc. Common Stock in Q3 2023, selling an estimated $13.7M.
  • Soleus Capital Management's ten largest holdings make up 43% of its $1.08B portfolio in Q3 2023.
  • Soleus Capital Management opened 25 new positions and closed 35 in Q3 2023.
  • Soleus Capital Management's portfolio value rose 20% quarter-over-quarter to $1.08B.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.